Metabolic effects of metformin in patients with type 2 diabetes mellitus and new coronavirus infection
- Autores: Zhurtova I.B.1, Gubachikova A.M.1, Aramisova L.S.1, Anaeva L.A.1, Abdul Moati H.A.1
-
Afiliações:
- Kabardino-Balkarian State University n.a. Kh.M. Berbekov
- Edição: Volume 30, Nº 12 (2023)
- Páginas: 128-131
- Seção: Pharmacological properties of drugs
- URL: https://journals.eco-vector.com/2073-4034/article/view/626061
- DOI: https://doi.org/10.18565/pharmateca.2023.12.128-131
- ID: 626061
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Limited contraindications for use; lack of stimulation of insulin secretion; weight gain and an extremely low risk of hypoglycemic episodes determine the relevance of the use of metformin as a first-line drug in the treatment of type 2 diabetes mellitus (DM2). The potential of metformin is not limited to its use in DM2. Numerous studies determining the pleiotropic effects of metformin have expanded the range of use of this drug. The article presents various metabolic properties of metformin; which have a beneficial effect on the pathogenesis of various pathological conditions; a new coronavirus infection.
Palavras-chave
Texto integral
Sobre autores
Inessa Zhurtova
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Autor responsável pela correspondência
Email: zhin07@mail.ru
ORCID ID: 0000-0003-0668-1073
Dr. Sci. (Med.), Professor at the Department of Faculty Therapy
Rússia, NalchikA. Gubachikova
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: zhin07@mail.ru
ORCID ID: 0000-0002-0017-011X
Department of Faculty Therapy; Medical Academy
Rússia, NalchikL. Aramisova
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: zhin07@mail.ru
ORCID ID: 0000-0001-8105-4235
Department of Faculty Therapy; Medical Academy
Rússia, NalchikL. Anaeva
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: zhin07@mail.ru
ORCID ID: 0000-0001-8421-8661
Department of Faculty Therapy, Medical Academy
Rússia, NalchikH. Abdul Moati
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: zhin07@mail.ru
Department of Faculty Therapy, Medical Academy
Rússia, NalchikBibliografia
- Sterne J. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanidine. (N.N.D.G.). Maroc Med. 1957;36:1295–96.
- Bailey S.D. Metformin: A Historical review. Diabetol. 2017;60:1566–76. doi: 10.1007/s00125-017-4318-z.
- Rena G.; Hardy D.G.; Pearson E.R. Mechanisms of action of metformin. Diabetol. 2017;60(9):1577–85.
- Inzucchi S.E. Isn’t it time to change the paradigm of type 2 diabetes treatment? no! Diab Care. 2017;40(8):1128–32.
- Curd F.H.S.; Davey D.G.; Rose F.L. Studies of synthetic antimalarial drugs. Some derivatives of biguanide as new types of antimalarial substances with both therapeutic and causal-prophylactic activity. Ann Trope Honey Parasitol. 1945;39:208–16.
- Garcia E. 1949 Flumamine. Untraced publication from the Philippines. Cited by Sterne J in an interview (April 4; 1996) for Merck-Lipha published in Glucophage; serving diabetology for 40 years. Pasik C (ed). Lyon: Groupe Lipha; 1997;21:29.
- Сердечно–сосудистые заболевания и сахарный диабет – междисциплинарный подход к лечению пациента. [Cardiovascular diseases and diabetes mellitus an interdisciplinary approach to patient treatment. (In Russ.)]. URL: https://www.endocrincentr.ru/specialists/education/obrazovanie-v-nmic-endokrinologii/nauchno-prakticheskie–meropriyatiya/obuchayushchie–seminary-i-lekcii/serdechno–sosudistye-zabolevaniya-i-saharnyy-diabet-mezhdisciplinarnyy (дата обращения 17.07.2023 / access date 07/17/2023).
- IDF Diabetes Atlas; 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas-8th-edition.html.
- Аметов А.С.; Демидова Т.Ю.; Кочергина И.И. Эффективность препаратов метформина в лечении сахарного диабета 2-го типа. Медицинский совет. 2016;(3):30–7. [Ametov A.S.; Demidova T.Yu.; Kochergina I.I. The effectiveness of metformin drugs in the treatment of type 2 diabetes mellitus. Meditsinskiy sovet. 2016;(3):30–7. (In Russ.)]. doi: 10.21518/2079-701X-2016-3-30-37.
- Журтова И.Б.; Губачикова А.М.; Таова М.С.; Хачмахова Э.З. Дозозависимое влияние метформина на течение и исход новой короновирусной инфекции у пациентов с СД 2типа и ожирением. Актуальные вопросы медицины. Материалы 53-й научно-практической конференции студентов; аспирантов и молодых ученых. 2023. С. 21–4. [Zhurtova I.B.; Gubachikova A.M.; Taova M.S.; Khachmakhova E.Z. Dose-dependent effect of metformin on the course and outcome of a new coronavirus infection in patients with type 2 diabetes and obesity. Current issues in medicine. Materials of the 53rd scientific and practical conference of students; graduate students and young scientists. 2023. P. 21–4. (In Russ.)].
- Давыдов А.Л. Влияние метформина и манинила на показатели липидного обмена у больных сахарным диабетом типа 2. Проблемы эндокринологии. 2000;46(3):10–3. [Davydov A.L. The influence of metformin and maninil on lipid metabolism in patients with type 2 diabetes mellitus. Problemy endokrinologii. 2000;46(3):10–3. (In Russ.)].
- Bramante C.T.; Ingraham N.E.; Murray T.A.; et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1):e34–41. doi: 10.1016/S2666-7568(20)30033-7.
- Мкртумян А.М. Метформин – общепризнанный препарат первого выбора у больных сахарным диабетом 2-го типа. Медицинский совет. 2018;(4):20–7. [Mkrtumyan A.M. Metformin is a generally accepted drug of first choice in patients with type 2 diabetes mellitus. Meditsinskiy sovet. 2018;(4):20–7. (In Russ.)]. doi: 10.21518/2079-701X-20184-20-27.
- Diabetes Prevention Program Research Group. Diab Care. 2005;28:888–94.
- Diabetes Prevention Program Outcomes Study Research Group: prepared on behalf of the DPPOS Research Group. Diab Med. 2013;30(1):46–55.
- Мохорт Т.В. Метформин: реальные и потенциальные клинические сценарии. Медицинские новости. 2019;11:20–8. [Mokhort T.V. Metformin: real and potential clinical scenarios. Meditsinskiye novosti. 2019;11:20–8. (In Russ.)].
- Mary A.; Hartemann A.; Liabeuf S.; et al. Cardiovasc Diabetol. 2017;16(1):24.